
Moawia Mohammed Ali Elhassan: Ultrahypofractionated radiotherapy with SIB shows early safety in breast cancer
Moawia Mohammed Ali Elhassan, Associate Professor at the University of Gezira, shared a post on LinkedIn about a paper by Maia Dzhugashvili et al. published in International Journal of Radiation Oncology, Biology, Physics:
“A recently published case series in the Journal of Radiation Oncology – Biology – Physics demonstrated the clinical feasibility and safety of adjuvant ultrahypofractionated radiotherapy with simultaneous integrated boost (SIB) of 29 Gy to the tumor bed in patients with early-stage breast cancer, showing no excess of early adverse events. The authors recommend further investigation into late toxicities.”
Authors: Maia Dzhugashvili, Ana Serradilla, Jaume Fernández-Ibiza, Graciela García, Kirill Matskov Malinochka, Lisellot Torres, Antonio Serala, José Begara, Daniela Gonsalves, Juan José De la Cruz Troca, Philip Poortmans, Felipe Couñago, Escarlata López.
More posts featuring Moawia Mohammed Ali Elhassan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023